<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926859</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-ESPRIT</org_study_id>
    <nct_id>NCT02926859</nct_id>
  </id_info>
  <brief_title>Enhancing Recovery in Early Schizophrenia</brief_title>
  <official_title>Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current antipsychotic treatments of schizophrenia are only partially effective, and their use
      is often associated with serious side effects. Cannabidiol is a natural counterpart of the
      psychoactive component of marijuana, delta-9- tetrahydrocannabinol and has no psychotomimetic
      or addictive properties. In a controlled clinical trial of cannabidiol versus amisulpride in
      acute paranoid schizophrenia we showed a statistically significant clinical improvement in
      all symptoms clusters of schizophrenia compared to baseline with either treatment.
      Cannabidiol displayed a significantly superior side-effect profile in particular regarding
      prolactin elevation, extrapyramidal symptoms and weight gain. The favorable side-effect
      profile and potentially novel mechanism of action identify this molecule as a potential
      antipsychotic. However, long-term safety and efficacy data is still lacking. This study is to
      evaluate the efficacy and safety of the novel compound cannabidiol in the maintenance
      treatment of schizophrenia in comparison to placebo as an add-on to an established treatment
      with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone, in a 12-months,
      double-blind, parallel-group, randomized, placebo-controlled clinical trial. Thereby,
      relevant data on cannabidiol's antipsychotic potential will be gained.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause discontinuation</measure>
    <time_frame>within 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by PANSS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Positive and Negative Syndrome Scale (PANSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by CGI</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Clinical Global Impression (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by BSI-53</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Symptom Inventory (BSI-53)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Psychopathology assessed by FROGS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Functional Remission of General Schizophrenia (FROGS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Depression Scale</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Calgary Depression Scale for Schizophrenia (CDSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by GAF</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Global Assessment of Functioning (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by PSP</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Personal and Social Performance Scale (PSP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in social and occupational functioning assessed by EMA</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Ecological Momentary Assessment (EMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of life assessed by WHOQUOL-Bref</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>WHO Quality of Life-Bref (WHOQUOL-Bref)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of life assessed by LQLP</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Lancashire Quality of Life Profile (LQLP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by B-CATS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Cognitive Assessment Tool for Schizophrenia (B-CATS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by BACS</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Brief Assessment of Cognition in Schizophrenia (BACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by UPSA-B</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>University of California San Diego Performance based Skills Assessment (UPSA-B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by MASC</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Movie for the Assessment of Social Cognition (MASC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Neurocognition assessed by PFA</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Pictures of Facial Affect (PFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cumulative dose of concomitant or rescue medication</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Biomarker: alterations of endocannabinoids and lipdomic profiling</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects: weight gain</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>Body Mass Index, abdominal girth</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Vital Signs</measure>
    <time_frame>6, 9 and 12 month</time_frame>
    <description>heart rate, blood pressure, electrocardiography</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: UKU Side Effect rating scale</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: Evaluation of extrapyramidal symptoms (EPS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Side effects: physical and neurological examination</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Standard blood tests</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicidality Sverity Rating Scale (C-SSRS)</measure>
    <time_frame>6, 9 and 12 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol as add-on to individualized pharmacological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as add-on to individualized pharmacological treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol as add-on</intervention_name>
    <description>Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo as add-on</intervention_name>
    <description>Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90)

          -  First documented diagnosis of schizophrenia must not be no older than seven years.

          -  Patients must receive a stable dose of amisulpride, aripiprazole, olanzapine,
             quetiapine or risperidone (TAU: treatment as usual) at least 4 weeks prior to
             inclusion in the study to ensure that the maximal effect of the previous medication
             has been received.

          -  Initial PANSS total score of ≤ 75 at baseline.

          -  proper contraception in female patients of childbearing potential

          -  body mass index between 18 and 40.

        Exclusion Criteria:

          -  Lack of accountability

          -  positive urine drug-screening for illicit drugs at screening (except cannabinoids and
             benzodiazepines)

          -  serious suicidal risk at screening visit

          -  other relevant interferences of axis 1 according to diagnostic evaluation (MINI)
             including residual forms of schizophrenia.

          -  other relevant neurological or other medical disorders

          -  pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703 2321</phone>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathrin Rohleder, PhD</last_name>
    <phone>+49 621 1703 2333</phone>
    <email>rohleder@cimh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Markus Leweke, MD</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>2761</phone_ext>
      <email>leweke@cimh.de</email>
    </contact>
    <investigator>
      <last_name>F. Markus Leweke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Falkai, MD</last_name>
      <email>Peter.Falkai@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Peter Falkai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte</name>
      <address>
        <city>Berlin</city>
        <state>B</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Walter, MD, PhD</last_name>
      <email>henrik.walter@charite.de</email>
    </contact>
    <investigator>
      <last_name>Henrik Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry Psychotherapy and Psychosomatics, RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Veselinovic, MD</last_name>
      <email>tveselinovic@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Tanja Veselinovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Jessen, MD</last_name>
      <email>frank.jessen@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Frank Jessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

